MedCost Clear Cost calculator

Insurance / Medicare / Wegovy

Does Medicare cover Wegovy?

From CMS's Part D formulary files for 2026 and 2027 plans, Medicare.gov, CMS and the FDA label. We count plans; we don't recommend one.

Short answer

Not for weight loss alone: Medicare Part D does not cover GLP-1 drugs used for weight loss.1Part D plans can cover Wegovy to lower heart attack and stroke risk in adults with heart disease and obesity or overweight, or for MASH (a fatty liver disease with liver scarring), with plan rules such as prior authorization.2345In CMS's formulary files, 175 of 5,496 (3.2%) Part D plans list Wegovy for 2026 and all 5,492 for 2027, every one of them with prior authorization.67For weight management, the Medicare GLP-1 Bridge covers Wegovy: if you qualify, you pay a $50 copayment for a one-month supply, through December 31, 2027.8910Why every 2027 plan lists it: Medicare's negotiated price for semaglutide starts January 1, 2027, and the law requires Part D plans to include drugs with a negotiated price in effect (see below).

Source: CMS formulary files published Sep 23, 2026 (2026 plans) and Oct 15, 2026 (2027 plans); Medicare.gov and CMS rules checked Oct 17, 2026

How many Part D plans list Wegovy

Every Medicare drug plan in CMS's file: standalone drug plans (PDP) and Medicare Advantage plans with drug coverage, including special needs plans. A plan counts when its drug list (formulary) has at least one form or strength of Wegovy. These are counts of plans, not of people enrolled in them.

Plan yearPlans that list itSharePrior auth.Quantity limitStep therapy
2026 175 of 5,496 3.2% 175 60 0
2026 · injection 175 of 5,496 3.2% 175 50 0
2026 · tablet (pill) 49 of 5,496 0.9% 49 49 0
2027 5,492 of 5,492 100% 5,492 5,369 0
2027 · injection 5,492 of 5,492 100% 5,492 5,355 0
2027 · tablet (pill) 5,492 of 5,492 100% 5,492 5,369 0
CMS formulary files: 2026_20260916.zip (published Sep 23, 2026) and 2027_20261008.zip (published Oct 15, 2026).

Which tier plans put it on

The lowest tier each listing plan gives Wegovy. Each plan can divide its tiers in different ways; generally, a drug in a lower tier costs you less than one in a higher tier.11 Your cost depends on your plan.

Plan yearTier 1Tier 2Tier 3Tier 4Tier 5Tier 6
202617112510220
20271233135,056000

Why every 2027 Part D plan lists Wegovy

Semaglutide, sold as Ozempic, Rybelsus and Wegovy, is one of the drugs Medicare negotiated a price for. From January 1, 2027, the negotiated price is $274 for a 30-day supply ($959 list price in 2024, 71% lower); for a box of four Wegovy 2.4 mg pens (NDC 00169-4524-14) CMS gives $385.63.121314 CMS's fact sheet on those prices says:

“As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
CMS: Medicare Drug Price Negotiation Program, Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) · as of Oct 23, 2026

By state

Each cell: the share of the state's Part D plans that list Wegovy, and the count. A plan counts in every state where it is sold. Medicare Advantage plans are sold by county, so a state's number includes plans sold in only part of the state. To see the plans for your ZIP code and your drugs, use Medicare Plan Finder; before joining a plan, Medicare.gov says to review its formulary to check if it covers the drugs you take.22

State2026 plans2027 plans
Alabama 0%
0 of 102
100%
115 of 115
Alaska 0%
0 of 9
100%
9 of 9
Arizona 0%
0 of 136
100%
148 of 148
Arkansas 0%
0 of 93
100%
86 of 86
California 13.1%
52 of 397
100%
397 of 397
Colorado 13.2%
14 of 106
100%
106 of 106
Connecticut 0%
0 of 53
100%
54 of 54
Delaware 4.8%
2 of 42
100%
43 of 43
District of Columbia 12.0%
3 of 25
100%
21 of 21
Florida 1.8%
11 of 597
100%
549 of 549
Georgia 5.2%
8 of 154
100%
151 of 151
Hawaii 13.0%
6 of 46
100%
50 of 50
Idaho 0%
0 of 50
100%
45 of 45
Illinois 0%
0 of 150
100%
133 of 133
Indiana 0%
0 of 128
100%
140 of 140
Iowa 0%
0 of 65
100%
64 of 64
Kansas 0%
0 of 89
100%
84 of 84
Kentucky 0%
0 of 115
100%
123 of 123
Louisiana 0.9%
1 of 114
100%
126 of 126
Maine 0%
0 of 54
100%
52 of 52
Maryland 15.9%
10 of 63
100%
49 of 49
Massachusetts 8.3%
8 of 96
100%
89 of 89
Michigan 0.5%
1 of 190
100%
183 of 183
Minnesota 2.5%
2 of 80
100%
63 of 63
Mississippi 0%
0 of 96
100%
105 of 105
Missouri 0%
0 of 155
100%
171 of 171
Montana 0%
0 of 36
100%
27 of 27
Nebraska 0%
0 of 55
100%
51 of 51
Nevada 0%
0 of 110
100%
100 of 100
New Hampshire 0%
0 of 25
100%
25 of 25
New Jersey 0%
0 of 85
100%
74 of 74
New Mexico 0%
0 of 78
100%
68 of 68
New York 1.5%
3 of 202
100%
215 of 215
North Carolina 1.7%
3 of 173
100%
177 of 177
North Dakota 0%
0 of 33
100%
26 of 26
Ohio 0%
0 of 205
100%
173 of 173
Oklahoma 0%
0 of 82
100%
81 of 81
Oregon 4.1%
4 of 97
100%
92 of 92
Pennsylvania 0.6%
2 of 319
100%
324 of 324
Rhode Island 0%
0 of 31
100%
29 of 29
South Carolina 1.1%
1 of 93
100%
91 of 91
South Dakota 0%
0 of 30
100%
30 of 30
Tennessee 0%
0 of 135
100%
157 of 157
Texas 0%
0 of 407
100%
412 of 412
Utah 0%
0 of 58
100%
53 of 53
Vermont 0%
0 of 13
100%
14 of 14
Virginia 4.3%
6 of 138
100%
145 of 145
Washington 15.2%
19 of 125
100%
114 of 114
West Virginia 0%
0 of 72
100%
70 of 70
Wisconsin 0%
0 of 99
100%
97 of 97
Wyoming 0%
0 of 19
100%
13 of 13
Puerto Rico 33.8%
22 of 65
100%
64 of 64
Virgin Islands 0%
0 of 1
100%
1 of 1
Guam 0%
0 of 1
100%
1 of 1
American Samoa 0%
0 of 1
100%
1 of 1
Northern Mariana Islands 0%
0 of 1
100%
1 of 1
Counted from the CMS files above. Data: Medicare Part D GLP-1 Formulary Coverage by State (CSV, JSON).

What a plan's drug list, tiers, prior authorization, quantity limits, step therapy and exceptions mean, for every Part D drug: "On the plan's drug list," explained · what Part D costs (deductible, out-of-pocket limit, Extra Help): Part D costs · denied? how to appeal, with your deadlines (including Wegovy prescribed to lower heart risk).

Uses Part D can cover

The FDA label's uses for Wegovy other than weight loss:

For these uses, CMS says your prescriber completes the Part D plan's own requirements, such as prior authorization.3

For weight management: the Medicare GLP-1 Bridge

Both Wegovy forms are on the Medicare GLP-1 Bridge list: the injection and the tablet.8 If you qualify, you pay a $50 copayment to the pharmacy for a one-month supply, through December 31, 2027.910 Who qualifies, how to get it and how it works with Part D (the same for every Bridge drug): the Medicare GLP-1 Bridge, in full.

The maker's self-pay price

The lowest listed price is shown, with its strength; your prescriber decides the strength. Click a form for every strength.

FormLowest listed self-pay priceOn the Bridge list
Wegovy
Prefilled pen (injection)
$349 / month
0.25 mg24
Yes
Wegovy
Tablet
$149 / month
1.5 mg25
Yes
Self-pay prices: the makers' listings on TrumpRx.gov, as of Oct 17, 2026. Bridge list: Medicare.gov, checked Nov 5, 2026.

How we counted

How this page is kept current

  • CMS and Medicare.gov pages and fact sheets: archived daily.
  • CMS Part D formulary files (which plans list which drugs): CMS publishes a new file monthly; we check for one weekly (Wednesdays). A person downloads and archives the new file, and the plan counts change when we rebuild from it.
  • Every change in an archived copy is flagged for a person to check against the official page; the site is updated only after that check. Nothing is published automatically. Changes: price change log · mistakes: corrections · all sources: sources and update schedule.

Free help from a person

Government programs only · no cost
  • SHIP (State Health Insurance Assistance Program): free, one-on-one Medicare counseling from a national government program with a SHIP in every state.29 SHIP counselors help you choose a plan, review coverage, understand costs, apply for Extra Help, and file a complaint or an appeal. Find your SHIP.2728
  • Medicare: 1-800-MEDICARE (1-800-633-4227); TTY 1-877-486-2048, 24 hours a day, 7 days a week (except some federal holidays), or live chat on Medicare.gov.26

We list only government and government-funded programs. We take no money from anyone listed here, and we do not pass your details to anyone.

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Other Medicare questions

Official sources for this page (29)
  1. “If a provider submits a prior authorization request to a Part D plan sponsor for a GLP-1 product that is excluded from coverage under Medicare Part D (agents when used for weight loss) but may be eligible for coverage under the Medicare GLP-1 Bridge, CMS strongly encourages the Part D plan sponsor to assist with directing the claim to the Medicare GLP-1 Bridge for review.”
  2. “For example, beneficiaries prescribed Zepbound® for the treatment of moderate to severe obstructive sleep apnea in adults with obesity or Wegovy® to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight should continue to receive coverage through Medicare Part D.”
  3. “When a provider prescribes a GLP-1 drug for a beneficiary for a use covered under the basic Part D benefit (e.g. Zepbound® for the treatment of moderate to severe obstructive sleep apnea in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight) the provider will need to complete the applicable utilization management requirements through the beneficiary’s Part D plan.”
  4. “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.”
  5. “for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.”
  6. “Starting July 1, 2026, Medicare covers these GLP-1 drugs: Foundayo® (tablet) Wegovy® (injection or tablet) Zepbound® (KwikPen® only. The program doesn’t cover single-dose Zepbound® vials or pens).”
    Medicare.gov: Weight loss drugs · as of Nov 5, 2026
  7. “You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
    Medicare.gov: Weight loss drugs · as of Nov 5, 2026
  8. “The Centers for Medicare & Medicaid Services (CMS) is extending the Medicare GLP-1 Bridge through December 31, 2027.”
    CMS HPMS memo, April 21, 2026 · as of Oct 17, 2026
  9. “Each plan can divide its tiers in different ways. Generally, a drug in a lower tier will cost you less than a drug in a higher tier.”
  10. “Ozempic; Rybelsus; Wegovy Novo Nordisk Inc. Type 2 diabetes; Type 2 diabetes and cardiovascular disease; Cardiovascular disease and obesity/ overweight $274 $959 71% $15,161,908,000 2,282,000”
  11. “00169-4524-14 2.4 mg /0.75 mL Pen, 4 Pens (Wegovy) $385.63”
  12. “These negotiated prices will become effective on January 1, 2027.”
  13. “Section 11001(b) of the IRA added section 1860D-4(b)(3)(I)(i) of the Act to require that for 2026 and each subsequent year, Part D plans include each covered Part D drug that is a selected drug under section 1192 of the Act on Part D formularies if an MFP is in effect for that drug with respect to that year.”
  14. “For 2026, 2027, and 2028, we have implemented this requirement through guidance.”
  15. “(vii) Except as specified in paragraph (b)(2)(viii) of this section, for 2026 and each subsequent year, include each Part D drug that is a selected drug under section 1192 of the Act for which a maximum fair price (as defined in section 1191(c)(3) of the Act) is in effect with respect to the year.”
  16. “Applicability date: These regulations are applicable to the Negotiation Program beginning with respect to initial price applicability year 2029 and to Part D Program coverage beginning January 1, 2029.”
  17. “At this time, we are not imposing tier placement, utilization management, or other special formulary requirements for selected drugs.”
  18. “we believe our current approach provides Part D plan sponsors with the flexibility to continue to manage costs through utilization management in a clinically appropriate manner, while allowing us to monitor practices that may undermine beneficiary access to selected drugs and potentially inform new requirements for future contract years.”
  19. “A participating drug company with a selected drug is required to ensure the negotiated price is made available to eligible individuals and to the pharmacies, mail-order services, and other entities that dispense the selected drug with respect to such individuals.”
  20. “Before joining a plan, be sure to review its formulary to check if it covers the drugs you take.”
  21. “TrumpRx and other types of discount cards aren’t considered creditable coverage. When you use them (instead of your Medicare plan) to buy drugs, it doesn’t count toward your Medicare deductible or out-of-pocket maximum.”
    Medicare.gov: Weight loss drugs · as of Nov 5, 2026
  22. “Limited Time Offer – New patients pay $199* for the first two monthly fills of Wegovy® (semaglutide) injection 0.25mg and 0.5mg, then $349/month. Only available for 2 monthly fills between 11/17/2025- 12/31/2026. For each fill after, pay $349/month for Wegovy® 0.25mg, 0.5mg, 1mg, 1.7mg, or 2.4mg and $399/month for Wegovy® HD 7.2mg.”
  23. “Self-pay pricing varies by dose. Eligibility and restrictions apply. Government beneficiaries excluded. One month is defined as one bottle containing 30 tablets. Novo Nordisk reserves the right to modify or cancel this offer at any time. See full Terms and Conditions.”
  24. “You can talk or live chat with a real person, 24 hours a day, 7 days a week (except some federal holidays.) 1-800-MEDICARE (1-800-633-4227) TTY users can call 1-877-486-2048”
    Medicare.gov: Talk to someone · as of Oct 30, 2026
  25. “Get free health insurance counseling State Health Insurance Assistance Programs (SHIPs) help people with Medicare and their families: Choose a plan Review coverage Understand costs Apply for Extra Help File a complaint or an appeal”
    Medicare.gov: Talk to someone · as of Oct 30, 2026
  26. “SHIP is a national program that offers one-on-one assistance, counseling, and education to Medicare beneficiaries, their families, and caregivers to help them make informed decisions about their care and benefits.”
  27. “There are 54 SHIP grantees (one in each of the 50 states, Puerto Rico, Guam, the District of Columbia, and the U.S. Virgin Islands).”

Did this page answer your question?